MDxHealth SA (NASDAQ:MDXH) Receives Average Rating of “Hold” from Analysts

Shares of MDxHealth SA (NASDAQ:MDXH) have been given a consensus recommendation of “Hold” by the five research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $3.50.

Several analysts have weighed in on MDXH shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of MDxHealth in a research note on Friday, March 27th. Wall Street Zen lowered shares of MDxHealth from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. TD Cowen reaffirmed a “buy” rating and set a $1.50 target price (down from $7.00) on shares of MDxHealth in a report on Thursday, May 14th. BTIG Research dropped their price target on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, May 14th. Finally, William Blair downgraded shares of MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th.

Institutional Trading of MDxHealth

Institutional investors have recently modified their holdings of the stock. Intesa Sanpaolo Wealth Management acquired a new position in shares of MDxHealth in the 4th quarter valued at approximately $36,000. Lido Advisors LLC acquired a new stake in shares of MDxHealth during the 3rd quarter worth approximately $48,000. Citadel Advisors LLC increased its stake in MDxHealth by 30.6% in the third quarter. Citadel Advisors LLC now owns 48,938 shares of the company’s stock valued at $228,000 after acquiring an additional 11,456 shares during the last quarter. Jefferies Financial Group Inc. bought a new position in MDxHealth in the third quarter valued at approximately $53,000. Finally, Squarepoint Ops LLC acquired a new position in MDxHealth during the fourth quarter valued at approximately $51,000.

MDxHealth Trading Down 1.4%

MDXH stock opened at $0.42 on Tuesday. MDxHealth has a 1-year low of $0.40 and a 1-year high of $5.33. The business’s 50 day simple moving average is $0.64 and its 200 day simple moving average is $2.19. The firm has a market capitalization of $20.63 million, a PE ratio of -0.64 and a beta of 1.43.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The business had revenue of $23.90 million during the quarter, compared to analyst estimates of $30.89 million. As a group, sell-side analysts predict that MDxHealth will post -0.6 EPS for the current fiscal year.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.